Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

H. A. Austin, J. H. Klippel, J. E. Balow, N. G. le Riche, A. D. Steinberg, P. H. Plotz, J. L. Decker

Research output: Contribution to journalArticlepeer-review

Abstract

We evaluated renal function in 107 patients with active lupus nephritis who participated in long-term randomized therapeutic trials (median follow-up, seven years). For patients taking oral prednisone alone, the probability of renal failure began to increase substantally after five years of observation. Renal function was better preserved in patients who received various cytotoxic-drug therapies, but the difference was statistically significant only for intravenous cyclophosphamide plus low-dose prednisone as compared with high-dose prednisone alone (P = 0.027). The advantage of treatment with intravenous cyclophosphamide over oral prednisone alone was particularly apparent in the high-risk subgroup of patients who had chronic histologic changes on renal biopsy at study entry. Patients treated with intravenous cyclophosphamide have not experienced hemorrhagic cystitis, cancer, or a disproportionate number of major infections. We conclude that, as compared with high-dose oral prednisone alone, treatment of lupus glomerulonephritis with intravenous cyclophosphamide reduces the risk of end-stage renal failure with few serious complications.

Original languageEnglish (US)
Pages (from-to)614-619
Number of pages6
JournalNew England Journal of Medicine
Volume314
Issue number10
StatePublished - 1986
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs'. Together they form a unique fingerprint.

Cite this